Latest News Release

Oncolytics Biotech Announces Positive Interim Safety Results from REOLYSIN® Phase I Malignant Glioma Study

ONCOLYTICS CLOSES PRIVATE PLACEMENT

ONCOLYTICS INCREASES SIZE OF PRIVATE PLACEMENT

ONCOLYTICS ANNOUNCES PRIVATE PLACEMENT

ONCOLYTICS BIOTECH ANNOUNCES 2002 THIRD QUARTER RESULTS

Oncolytics Biotech Appoints Dr. William A. Cochrane to the Board of Directors

Oncolytics Biotech to Present at 4th Annual Techvest LLC Healthcare Conference

Oncolytics Biotech Announces Appointment of Senior Vice President, Clinical and Regulatory Affairs


Year

Oncolytics Biotech® Announces Poster Presentation at the 2018 Gastrointestinal Cancers Symposium Sponsored by ASCO in Patients with Relapsed Metastatic Adenocarcinoma of the Pancreas Read More

Oncolytics Biotech® Receives Favorable Final Advice Letter from the European Medicines Agency for REOLYSIN® in Metastatic Breast Cancer Read More

View all news articles

Exploring REOLYSIN®’s Objective Response Rate in Females with Colorectal Cancer Read More

Exploring REOLYSIN<sup>®</sup>’s Objective Response Rate in Females with Colorectal Cancer thumbail
View all blog posts

LATEST TWEETS

Follow us on Twitter